邮 箱:info@tlph.com.la
English
新闻
东盟制药:持续参与“一带一路”国际医疗合作
FGFR抑制剂Erdafitinib厄达替尼降低73%(不限瘤种)晚期实体瘤肿瘤负荷!
东盟制药防伪查询系统,协助患者维护自身权益
激战肺癌!东盟制药索托拉西布片上市!
赠送免费新冠特效药,东盟制药莫努匹韦协助肿瘤患者抗击新冠
依鲁替尼+阿卡替尼:东盟制药BTK之战
老挝东盟制药(TLPH)吉瑞替尼Giruini(Gilteritinib)上市!
东盟制药通过GMP认证 成就高品质好药
首款MET抑制剂!东盟制药特泊替尼上市!
重品质,认品牌!老挝东盟制药提醒:患者谨防掉入仿制药“低价陷阱"
东盟制药(TLPH) 厄达替尼Erdaini(Erdafitinib)上市!
东盟制药:巴瑞替尼对重症斑秃疗效显著
老挝东盟制药他达那非片获准上市!
东盟制药:科学用药助力个人防疫新时代
老挝东盟制药:新的产品防伪系统效果显著!
总缓解率97%!老挝东盟制药阿卡替尼获批!
不限癌种!老挝东盟制药拉罗替尼上市!
警惕!东盟制药曝光假药产业链!
东盟制药:没有新防伪标贴的产品均属假冒
东盟制药:运用科技手段 保障用药安全
东盟制药:FDA批准巴瑞替尼治疗斑秃
全新升级!东盟制药产品防伪系统上线!
实锤!老挝东盟制药曝光假冒产品!
东盟制药莫努匹韦获卫生部使用推荐
东盟制药:FDA批准恩格列净治疗心衰
重磅!东盟制药莫努匹韦获批上市!
老挝东盟制药:共克时艰 共襄盛举
东盟制药尼拉帕利(Niraparib)获准上市
老挝东盟制药劳拉替尼重磅上市
老挝东盟制药(TLPH)奥拉帕尼(片剂)获准上市
老挝东盟卡博替尼广受欢迎
东盟制药:卡博替尼效果显著
东盟制药生产许可证换证顺利获批
东盟制药:恩曲替尼安全性高
东盟制药(TLPH)艾曲波帕安全性高
东盟制药(TLPH)巴瑞克替尼效果显著!
老挝东盟制药(TLPH)恩曲替尼重磅上市
老挝东盟制药(TLPH)卡博替尼获准上市
东盟制药通过GMP认证 高标准成就高品质
湖北临床肿瘤学会访问老挝 积极推动国际医疗合作
东盟制药:老挝药竞争力稳步提升
ບໍລິດສັດລາວຕຸງເມິງຈັດກິດຈະກຳມອບເຄື່ອງຊ່ວຍ ເຫຼືອໃຫ້
The First Session of Belt and Road ofLaos-China Ho
ສປປ ລາວ ເຂົ້າເປັນ ສະມາຊິກສົມບູນຂອງ WHO ກ່ຽວກັບການຕ
The First Session of Belt and Road ofLaos-China Ho
With the common vision of China “The Belt and Road” of construction Health Silk Road, establishing...
说明书下载
产品介绍

With the common vision of China “The Belt and Road” of construction Health Silk Road, establishing the interactive platform for hospital to hospital, professional medical staff people to people in Laos and China, and for clinical diagnosis and treatment, and academic inter exchange, has become the top priority of international medical cooperation. In order to understand and master the current situation and latest progress in the prevention and treatment of infectious diseases, especially the liver diseases represented by viral hepatitis, AIDS and dengue fever diagnosis and treatment, and to develop the clinic exchanges and cooperation in tumor targeted therapy among countries, the Department of Health Care, Ministry of Health of Laos will hold The First Session of Belt and Road (Healthy Silk Road) of Laos-China Hospitals International Exchange & Cooperation Forum, and Laos International Symposium on Infectious Prevention & Treatment and Tumor Clinical Diagnosis & Treatment on October 27th in Vientiane, Laos.

The Session was led by the Department of Health Care, Ministry of Health of Laos, and undertaken by the Mittaphab Hospital of Laos. The conference specially invited the Deputy Health Minister of Laos, Mr. Phouthonet, the Director of General of Department of Health Care, Mr. Bounnack, the Director of Mittaphab Hospital, Mr. Snong and the director of Sichuan Mianyang 404 Hospita, Mr. Jiang to publish the speech at the opening ceremony. Then Phetsamone Arounlangsy(the leader of the field of health system for tumor of Laos), Hu Xiaohua(the director of Oncology Department of the First Affiliated Hospital of Guangxi Medical University), Wang Yuling(the vice director of the Fifth Hospital of Shijiazhuang), Liu Bing(the vice director of Center for Infectious Disease Prevention) and Cheng Changsheng(the vice director of Infectious Disease Quality Control Center of Guangxi Health Department) made special report on the progress of disease research and hotpot issues discussion about hospital management on the meeting.

In the speech of the opening ceremony of the Session, the Deputy Health Minister of Laos, Mr. Phouthone said , since 2013, the “Belt and Road Initiative” of Republic of China has been proposed and currently, this initiative is becoming a reality and bearing fruit. The “Belt and Road Initiative” aims to built trade and infrastructure networks connecting Asia, Europe and Africa to seek common development and prosperity.

(the Deputy Health Minister of Laos, Mr. Phouthone)

Mr. Phouthone claimed that they strongly support cooperation in medical science, epidemic prevention as well as clinical research to improve the quality of health of people in the world. Finally, Mr. Phouthone gave his appreciation to the “Belt and Road initiative”, which deepened the collaboration between Laos and China. He said he hoped that the collaboration would be improved to the full extent.

(Mr.Jiang has been awarded the Medical cooperation Contribution of the “Belt and Road” by the Deputy Health Minister of Laos, Mr. Phouthonet)

It is understood that the conference report involves a number of important topics such as Achievement report on the clinical application of DAA drugs in the treatment of CHC in Laos or China, The role of Interventional therapy in the treatment of pulmonary tuberculosis, Targeted therapy for NSCLC and Multi-center Theory and Clinical Strategy of Hepatocellular Carcinoma. After the meeting, each teaching expert was awarded the commemorative certificate issued by Mittaphab Hospital. After the Session, all the experts visited the co-organizer of the International Symposium—Tongmeng(Lao) PharmacEutical & Food Co.,Ltd together ( the medical provider of the government health-care programs in Laos).Experts participating in the conference believed that it has more far-reaching significance for the seminar started from many fields of infectious diseases. It will helpful to develop the clinic exchanges and cooperation in tumor targeted therapy among countries.

launched health follow-up work and as one of the practical actions to practice the “Belt and Road Initiative”. He hoped that the session would be a good start. In the future, the international medical conference between China and Laos will be normalization and continue to be held. From China to Laos, “Belt and Road (Healthy Silk Road)” will walk further and further.

(the Director of Mittaphab Hospital, Mr. Snong)

 

 



其他产品
联系我们
地 址: Rd.13 South, 31 km Ban Naphasuk, SaithanyDistrict, Vientiane, Lao PDR
邮 箱: info@tlph.com.la
微 信: TLPH01
网 址: https: //tlph.com.la
Copyright © 2017 TLPH. All rights reserved. 技术支持:建站100
Copyright © 2017 TLPH. All rights reserved.
技术支持:建站100